« EMC Well-Positioned To Capitalize On Robust Demand
Sempra Seen As A Top Pick In Electricity »

ViroPharma’s Phase II Data ‘Introduces Some Uncertainty’

Piper Jaffray maintained a “market perform” rating on the drugmaker.


From www.forbes.com/markets/2006/03/31/viropharma-0331markets12.html?partner=rss ]]>”>Forbes Market Updates

This entry was posted on Friday, March 31st, 2006 at 9:00 pm and is filed under General updates. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Comments are closed.